Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2022-02-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
联合资信评估股份有限公司关于天康生物股份有限公司2021年度业绩预告的关注公告
Regulatory Filings Classification · 95% confidence The document is a notice from a credit rating agency (联合资信评估股份有限公司) regarding the 2021 annual performance forecast of 天康生物股份有限公司. It discusses the company's expected net loss for 2021 and the reasons behind it, as well as the impact on the company's credit rating and bonds. The document is relatively short (878 characters) and serves as an announcement or commentary on the company's performance forecast rather than the full annual report or financial statements. It does not contain detailed financial data or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not fit into categories like Earnings Release or Management Reports because it is issued by a rating agency focusing on credit implications. Therefore, it is best classified as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements and notices that do not fit other specific categories.
2022-02-08 Chinese
2021年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2021年度业绩预告' which translates to '2021 Annual Performance Forecast'. It provides estimated financial results for the full year 2021, including expected net profit/loss and earnings per share. The document explicitly states that the data is preliminary, unaudited, and based on internal estimates, with final audited results to be disclosed in the 2021 Annual Report. The document length is short (1272 characters) and it is an announcement of expected financial performance rather than a full financial report. Therefore, it is an Earnings Release (ER) type document, as it announces key financial highlights for the period but does not contain full audited financial statements or detailed analysis. FY 2021
2022-01-28 Chinese
天康生物股份有限公司章程（修订稿）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Tian Kang Biology Co., Ltd. It contains detailed provisions on company organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. It references Chinese company law, securities law, and stock exchange listing rules. The content is a comprehensive governance document setting out the company's internal rules and structure rather than a financial report or announcement. It is not an Annual Report, Interim Report, Earnings Release, nor a Meeting Announcement or Voting Results. It is not a proxy statement or remuneration report. The document is a governance charter or bylaws, which fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not a brief announcement or summary.
2022-01-26 Chinese
第七届董事会第二十四次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a specific board meeting of Tian Kang Bio Co., Ltd. It details the approval of proposals related to commodity futures hedging business, changes in registered capital and amendments to the company bylaws, and the scheduling of a shareholders meeting. The document includes voting results and references to other announcements and approvals but does not contain financial statements or detailed financial analysis. It is primarily a board meeting resolution announcement, not a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG). The document length is under 5,000 characters and is a meeting resolution announcement, not a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2022-01-26 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司开展商品期货套期保值业务的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from a securities company (中信建投证券股份有限公司) regarding the commodity futures hedging business of 天康生物股份有限公司. It discusses the purpose, accounting policies, risk analysis, risk control measures, and approvals related to the hedging business. The document includes independent directors' opinions and the sponsor's verification opinion. It is not a financial report like an annual or interim report, nor is it a brief announcement or voting result. It is a specialized audit or verification report related to internal controls and compliance for a specific business activity. Therefore, it fits best under Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content and detailed analysis, not just an announcement or certification, so it is not RPA or RNS. FY 2022
2022-01-26 Chinese
关于开展商品期货套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tian Kang Biological Co., Ltd. regarding the company's decision to engage in commodity futures hedging business using its own funds up to 1 billion RMB. It details the purpose, scope, risk analysis, risk control measures, and approvals related to this hedging activity. The document includes references to board resolutions, independent director opinions, and sponsor opinions, and it is dated January 27, 2022. The content is focused on informing shareholders and the market about a financing risk management activity rather than reporting financial results or providing detailed financial statements. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or a voting result announcement. The document is a regulatory announcement about a capital risk management strategy and business activity, fitting best under Capital/Financing Update (CAP). The document length is about 3100 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2022-01-26 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.